G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845","Liu Q., Lyu H., Xu B., Lee J.H. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–86. DOI: 10.1007/s00266-020-02083-5","Sia K.J., Tang I.P., Tan T.Y. Multiple symmetrical lipomatosis: case report and literature review. J Laryngol Otol. 2012;126(7):756–8. DOI: 10.1017/S0022215112000709","Kratz C., Lenard H.G., Ruzicka T., Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–7. DOI: 10.1053/ejpn.2000.0264","Nounla J., Rolle U., Gräfe G., Kräling K. Benign symmetric lipomatosis with myelomeningocele in an adolescent: An uncommon association-case report. J Pediatr Surg. 2001;36(7):E13. DOI: 10.1053/jpsu.2001.24776","Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30.","Lanois P.E., Bensaude R. De ladeno-lipomatosesymetrique. Bull Mem Soc Med Hosp. 1898;1:298.","El Ouahabi H., Doubi S., Lahlou K., Boujraf S., Ajdi F. Launois-bensaude syndrome: A benign symmetric lipomatosis without alcohol association. Ann Afr Med. 2017;16(1):33–4. DOI: 10.4103/1596-3519.202082","Chen C.Y., Fang Q.Q., Wang X.F., Zhang M.X., Zhao W.Y., Shi B.H., et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;3975974. DOI: 10.1155/2018/3975974","Coker J.E., Bryan J.A. Endocrine and metabolic disorders: Causes and pathogenesis of obesity. J. Fam. Pract. 2008;4:21–6.","González-García R., Rodríguez-Campo F.J., Sastre-Pérez J., Muñoz-Guerra M.F. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108– 12; discussion 113. DOI: 10.1007/s00266-004-3123-5","Holme E., Larsson N.G., Oldfors A., Tulinius M., Sahlin P., Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845"],"dc.citation.ru":["Liu Q., Lyu H., Xu B., Lee J.H. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–86. DOI: 10.1007/s00266-020-02083-5","Sia K.J., Tang I.P., Tan T.Y. Multiple symmetrical lipomatosis: case report and literature review. J Laryngol Otol. 2012;126(7):756–8. DOI: 10.1017/S0022215112000709","Kratz C., Lenard H.G., Ruzicka T., Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–7. DOI: 10.1053/ejpn.2000.0264","Nounla J., Rolle U., Gräfe G., Kräling K. Benign symmetric lipomatosis with myelomeningocele in an adolescent: An uncommon association-case report. J Pediatr Surg. 2001;36(7):E13. DOI: 10.1053/jpsu.2001.24776","Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30.","Lanois P.E., Bensaude R. De ladeno-lipomatosesymetrique. Bull Mem Soc Med Hosp. 1898;1:298.","El Ouahabi H., Doubi S., Lahlou K., Boujraf S., Ajdi F. Launois-bensaude syndrome: A benign symmetric lipomatosis without alcohol association. Ann Afr Med. 2017;16(1):33–4. DOI: 10.4103/1596-3519.202082","Chen C.Y., Fang Q.Q., Wang X.F., Zhang M.X., Zhao W.Y., Shi B.H., et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;3975974. DOI: 10.1155/2018/3975974","Coker J.E., Bryan J.A. Endocrine and metabolic disorders: Causes and pathogenesis of obesity. J. Fam. Pract. 2008;4:21–6.","González-García R., Rodríguez-Campo F.J., Sastre-Pérez J., Muñoz-Guerra M.F. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108– 12; discussion 113. DOI: 10.1007/s00266-004-3123-5","Holme E., Larsson N.G., Oldfors A., Tulinius M., Sahlin P., Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845"],"dc.citation.en":["Liu Q., Lyu H., Xu B., Lee J.H. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–86. DOI: 10.1007/s00266-020-02083-5","Sia K.J., Tang I.P., Tan T.Y. Multiple symmetrical lipomatosis: case report and literature review. J Laryngol Otol. 2012;126(7):756–8. DOI: 10.1017/S0022215112000709","Kratz C., Lenard H.G., Ruzicka T., Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–7. DOI: 10.1053/ejpn.2000.0264","Nounla J., Rolle U., Gräfe G., Kräling K. Benign symmetric lipomatosis with myelomeningocele in an adolescent: An uncommon association-case report. J Pediatr Surg. 2001;36(7):E13. DOI: 10.1053/jpsu.2001.24776","Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30.","Lanois P.E., Bensaude R. De ladeno-lipomatosesymetrique. Bull Mem Soc Med Hosp. 1898;1:298.","El Ouahabi H., Doubi S., Lahlou K., Boujraf S., Ajdi F. Launois-bensaude syndrome: A benign symmetric lipomatosis without alcohol association. Ann Afr Med. 2017;16(1):33–4. DOI: 10.4103/1596-3519.202082","Chen C.Y., Fang Q.Q., Wang X.F., Zhang M.X., Zhao W.Y., Shi B.H., et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;3975974. DOI: 10.1155/2018/3975974","Coker J.E., Bryan J.A. Endocrine and metabolic disorders: Causes and pathogenesis of obesity. J. Fam. Pract. 2008;4:21–6.","González-García R., Rodríguez-Campo F.J., Sastre-Pérez J., Muñoz-Guerra M.F. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108– 12; discussion 113. DOI: 10.1007/s00266-004-3123-5","Holme E., Larsson N.G., Oldfors A., Tulinius M., Sahlin P., Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845"],"dc.identifier.uri":["http://hdl.handle.net/123456789/8932"],"dc.date.accessioned_dt":"2025-07-09T13:59:02Z","dc.date.accessioned":["2025-07-09T13:59:02Z"],"dc.date.available":["2025-07-09T13:59:02Z"],"publication_grp":["123456789/8932"],"bi_4_dis_filter":["madelung’s disease\n|||\nMadelung’s disease","lipectomy\n|||\nlipectomy","диффузный симметричный липоматоз\n|||\nдиффузный симметричный липоматоз","шеи новообразования\n|||\nшеи новообразования","липэктомия\n|||\nлипэктомия","diffuse symmetric lipomatosis\n|||\ndiffuse symmetric lipomatosis","adipose tissue proliferation\n|||\nadipose tissue proliferation","жировой ткани разрастание\n|||\nжировой ткани разрастание","болезнь маделунга\n|||\nболезнь Маделунга","neck neoplasms\n|||\nneck neoplasms"],"bi_4_dis_partial":["липэктомия","Madelung’s disease","diffuse symmetric lipomatosis","neck neoplasms","болезнь Маделунга","adipose tissue proliferation","шеи новообразования","lipectomy","диффузный симметричный липоматоз","жировой ткани разрастание"],"bi_4_dis_value_filter":["липэктомия","Madelung’s disease","diffuse symmetric lipomatosis","neck neoplasms","болезнь Маделунга","adipose tissue proliferation","шеи новообразования","lipectomy","диффузный симметричный липоматоз","жировой ткани разрастание"],"bi_sort_1_sort":"systemic benign lipomatosis (madelung’s disease): experience of surgical treatment. clinical case","bi_sort_3_sort":"2025-07-09T13:59:02Z","read":["g0"],"_version_":1837178072511545344},{"SolrIndexer.lastIndexed":"2025-05-06T09:29:26.857Z","search.uniqueid":"2-7930","search.resourcetype":2,"search.resourceid":7930,"handle":"123456789/8819","location":["m229","l684"],"location.comm":["229"],"location.coll":["684"],"withdrawn":"false","discoverable":"true","author":["Gareev, Ilgiz","Beylerli, Ozal","Sufianov, Albert","Pavlov, Valentin","Shi, Huaizhang"],"author_keyword":["Gareev, Ilgiz","Beylerli, Ozal","Sufianov, Albert","Pavlov, Valentin","Shi, Huaizhang"],"author_ac":["gareev, ilgiz\n|||\nGareev, Ilgiz","beylerli, ozal\n|||\nBeylerli, Ozal","sufianov, albert\n|||\nSufianov, Albert","pavlov, valentin\n|||\nPavlov, Valentin","shi, huaizhang\n|||\nShi, Huaizhang"],"author_filter":["gareev, ilgiz\n|||\nGareev, Ilgiz","beylerli, ozal\n|||\nBeylerli, Ozal","sufianov, albert\n|||\nSufianov, Albert","pavlov, valentin\n|||\nPavlov, Valentin","shi, huaizhang\n|||\nShi, Huaizhang"],"dc.contributor.author_hl":["Gareev, Ilgiz","Beylerli, Ozal","Sufianov, Albert","Pavlov, Valentin","Shi, Huaizhang"],"dc.contributor.author_mlt":["Gareev, Ilgiz","Beylerli, Ozal","Sufianov, Albert","Pavlov, Valentin","Shi, Huaizhang"],"dc.contributor.author":["Gareev, Ilgiz","Beylerli, Ozal","Sufianov, Albert","Pavlov, Valentin","Shi, Huaizhang"],"dc.contributor.author_stored":["Gareev, Ilgiz\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Beylerli, Ozal\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Sufianov, Albert\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Pavlov, Valentin\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Shi, Huaizhang\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.contributor.author.en":["Gareev, Ilgiz","Beylerli, Ozal","Sufianov, Albert","Pavlov, Valentin","Shi, Huaizhang"],"dc.date.accessioned_dt":"2025-05-06T09:27:48Z","dc.date.accessioned":["2025-05-06T09:27:48Z"],"dc.date.available":["2025-05-06T09:27:48Z"],"dateIssued":["2025-01-01"],"dateIssued_keyword":["2025-01-01","2025"],"dateIssued_ac":["2025-01-01\n|||\n2025-01-01","2025"],"dateIssued.year":[2025],"dateIssued.year_sort":"2025","dc.date.issued_dt":"2025-01-01T00:00:00Z","dc.date.issued":["2025-01-01"],"dc.date.issued_stored":["2025-01-01\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.description.abstract_hl":["Intracerebral hemorrhage (ICH) is one of the most devastating and life-threatening forms of stroke, characterized by bleeding within the brain parenchyma. The condition is associated with a high mortality rate and significant long-term disabilities among survivors, underscoring the urgent need for innovative therapeutic strategies that go beyond managing symptoms to actively promote brain repair and functional recovery. Current treatment options are largely limited to supportive care, including surgical interventions to alleviate intracranial pressure and management of underlying risk factors such as hypertension. These approaches, however, fail to address the extensive neurological damage caused by ICH. Emerging evidence highlights the potential of stromal vascular fraction (SVF) cell therapy as a novel regenerative treatment for ICH. SVF, derived from adipose tissue through enzymatic digestion, is a heterogeneous mixture of cells, including mesenchymal stem cells (MSCs), endothelial cells, pericytes, immune cells, and progenitor cells. This cellular composition contributes synergistically to the repair and regeneration of damaged tissues. The mechanisms of action of SVF encompass inflammation modulation, neuroprotection, angiogenesis, and immunomodulation. MSCs within SVF release anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), reducing secondary injury caused by excessive inflammation. Endothelial cells and pericytes promote the formation of new blood vessels, restoring oxygen and nutrient supply to ischemic regions. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) further support neuronal survival and repair of neural circuits. Preclinical studies in animal models have consistently demonstrated the efficacy of SVF therapy, including reductions in brain edema, oxidative stress, and inflammatory cytokines, alongside improvements in angiogenesis, neuronal survival, and functional recovery. Early-phase clinical trials and case studies provide preliminary evidence of safety, feasibility, and potential therapeutic benefits in human patients with acute and chronic ICH. However, significant challenges remain, including the variability in SVF composition, optimal delivery methods, timing of intervention, and long-term safety considerations. This review comprehensively examines the biological properties of SVF, the mechanisms underlying its therapeutic effects, and the preclinical and clinical evidence supporting its use in ICH. Additionally, it explores future directions, including the development of standardized protocols, optimization of delivery techniques, integration with combination therapies, and the potential for personalized medicine approaches. As ongoing research and clinical trials refine these strategies, SVF therapy holds transformative potential to revolutionize ICH treatment by addressing its complex pathophysiology and improving patient outcomes. This novel approach not only promises to mitigate the immediate impacts of ICH but also offers hope for long-term recovery and enhanced quality of life for affected individuals. © 2025 International Hemorrhagic Stroke Association"],"dc.description.abstract":["Intracerebral hemorrhage (ICH) is one of the most devastating and life-threatening forms of stroke, characterized by bleeding within the brain parenchyma. The condition is associated with a high mortality rate and significant long-term disabilities among survivors, underscoring the urgent need for innovative therapeutic strategies that go beyond managing symptoms to actively promote brain repair and functional recovery. Current treatment options are largely limited to supportive care, including surgical interventions to alleviate intracranial pressure and management of underlying risk factors such as hypertension. These approaches, however, fail to address the extensive neurological damage caused by ICH. Emerging evidence highlights the potential of stromal vascular fraction (SVF) cell therapy as a novel regenerative treatment for ICH. SVF, derived from adipose tissue through enzymatic digestion, is a heterogeneous mixture of cells, including mesenchymal stem cells (MSCs), endothelial cells, pericytes, immune cells, and progenitor cells. This cellular composition contributes synergistically to the repair and regeneration of damaged tissues. The mechanisms of action of SVF encompass inflammation modulation, neuroprotection, angiogenesis, and immunomodulation. MSCs within SVF release anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), reducing secondary injury caused by excessive inflammation. Endothelial cells and pericytes promote the formation of new blood vessels, restoring oxygen and nutrient supply to ischemic regions. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) further support neuronal survival and repair of neural circuits. Preclinical studies in animal models have consistently demonstrated the efficacy of SVF therapy, including reductions in brain edema, oxidative stress, and inflammatory cytokines, alongside improvements in angiogenesis, neuronal survival, and functional recovery. Early-phase clinical trials and case studies provide preliminary evidence of safety, feasibility, and potential therapeutic benefits in human patients with acute and chronic ICH. However, significant challenges remain, including the variability in SVF composition, optimal delivery methods, timing of intervention, and long-term safety considerations. This review comprehensively examines the biological properties of SVF, the mechanisms underlying its therapeutic effects, and the preclinical and clinical evidence supporting its use in ICH. Additionally, it explores future directions, including the development of standardized protocols, optimization of delivery techniques, integration with combination therapies, and the potential for personalized medicine approaches. As ongoing research and clinical trials refine these strategies, SVF therapy holds transformative potential to revolutionize ICH treatment by addressing its complex pathophysiology and improving patient outcomes. This novel approach not only promises to mitigate the immediate impacts of ICH but also offers hope for long-term recovery and enhanced quality of life for affected individuals. © 2025 International Hemorrhagic Stroke Association"],"dc.description.abstract.en":["Intracerebral hemorrhage (ICH) is one of the most devastating and life-threatening forms of stroke, characterized by bleeding within the brain parenchyma. The condition is associated with a high mortality rate and significant long-term disabilities among survivors, underscoring the urgent need for innovative therapeutic strategies that go beyond managing symptoms to actively promote brain repair and functional recovery. Current treatment options are largely limited to supportive care, including surgical interventions to alleviate intracranial pressure and management of underlying risk factors such as hypertension. These approaches, however, fail to address the extensive neurological damage caused by ICH. Emerging evidence highlights the potential of stromal vascular fraction (SVF) cell therapy as a novel regenerative treatment for ICH. SVF, derived from adipose tissue through enzymatic digestion, is a heterogeneous mixture of cells, including mesenchymal stem cells (MSCs), endothelial cells, pericytes, immune cells, and progenitor cells. This cellular composition contributes synergistically to the repair and regeneration of damaged tissues. The mechanisms of action of SVF encompass inflammation modulation, neuroprotection, angiogenesis, and immunomodulation. MSCs within SVF release anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), reducing secondary injury caused by excessive inflammation. Endothelial cells and pericytes promote the formation of new blood vessels, restoring oxygen and nutrient supply to ischemic regions. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) further support neuronal survival and repair of neural circuits. Preclinical studies in animal models have consistently demonstrated the efficacy of SVF therapy, including reductions in brain edema, oxidative stress, and inflammatory cytokines, alongside improvements in angiogenesis, neuronal survival, and functional recovery. Early-phase clinical trials and case studies provide preliminary evidence of safety, feasibility, and potential therapeutic benefits in human patients with acute and chronic ICH. However, significant challenges remain, including the variability in SVF composition, optimal delivery methods, timing of intervention, and long-term safety considerations. This review comprehensively examines the biological properties of SVF, the mechanisms underlying its therapeutic effects, and the preclinical and clinical evidence supporting its use in ICH. Additionally, it explores future directions, including the development of standardized protocols, optimization of delivery techniques, integration with combination therapies, and the potential for personalized medicine approaches. As ongoing research and clinical trials refine these strategies, SVF therapy holds transformative potential to revolutionize ICH treatment by addressing its complex pathophysiology and improving patient outcomes. This novel approach not only promises to mitigate the immediate impacts of ICH but also offers hope for long-term recovery and enhanced quality of life for affected individuals. © 2025 International Hemorrhagic Stroke Association"],"dc.doi":["10.1016/j.hest.2025.01.002"],"dc.doi.en":["10.1016/j.hest.2025.01.002"],"dc.identifier.issn":["2589-238X"],"dc.identifier.uri":["http://hdl.handle.net/123456789/8819"],"dc.language.iso":["en"],"dc.language.iso.en":["en"],"dc.publisher":["KeAi Communications Co."],"dc.publisher.en":["KeAi Communications Co."],"dc.relation.ispartofseries":["Brain Hemorrhages;"],"dc.relation.ispartofseries.en":["Brain Hemorrhages;"],"subject":["Intracerebral hemorrhage","Mesenchymal stem cells","Neuroprotection","Regenerative medicine","Stroke treatment","Stromal vascular fraction","Scopus"],"subject_keyword":["Intracerebral hemorrhage","Intracerebral hemorrhage","Mesenchymal stem cells","Mesenchymal stem cells","Neuroprotection","Neuroprotection","Regenerative medicine","Regenerative medicine","Stroke treatment","Stroke treatment","Stromal vascular fraction","Stromal vascular fraction","Scopus","Scopus"],"subject_ac":["intracerebral hemorrhage\n|||\nIntracerebral hemorrhage","mesenchymal stem cells\n|||\nMesenchymal stem cells","neuroprotection\n|||\nNeuroprotection","regenerative medicine\n|||\nRegenerative medicine","stroke treatment\n|||\nStroke treatment","stromal vascular fraction\n|||\nStromal vascular fraction","scopus\n|||\nScopus"],"subject_tax_0_filter":["intracerebral hemorrhage\n|||\nIntracerebral hemorrhage","mesenchymal stem cells\n|||\nMesenchymal stem cells","neuroprotection\n|||\nNeuroprotection","regenerative medicine\n|||\nRegenerative medicine","stroke treatment\n|||\nStroke treatment","stromal vascular fraction\n|||\nStromal vascular fraction","scopus\n|||\nScopus"],"subject_filter":["intracerebral hemorrhage\n|||\nIntracerebral hemorrhage","mesenchymal stem cells\n|||\nMesenchymal stem cells","neuroprotection\n|||\nNeuroprotection","regenerative medicine\n|||\nRegenerative medicine","stroke treatment\n|||\nStroke treatment","stromal vascular fraction\n|||\nStromal vascular fraction","scopus\n|||\nScopus"],"dc.subject_mlt":["Intracerebral hemorrhage","Mesenchymal stem cells","Neuroprotection","Regenerative medicine","Stroke treatment","Stromal vascular fraction","Scopus"],"dc.subject":["Intracerebral hemorrhage","Mesenchymal stem cells","Neuroprotection","Regenerative medicine","Stroke treatment","Stromal vascular fraction","Scopus"],"dc.subject.en":["Intracerebral hemorrhage","Mesenchymal stem cells","Neuroprotection","Regenerative medicine","Stroke treatment","Stromal vascular fraction","Scopus"],"title":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"title_keyword":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"title_ac":["stromal vascular fraction cell therapy: a promising therapeutic method for intracerebral hemorrhage\n|||\nStromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.title_sort":"Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage","dc.title_hl":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.title_mlt":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.title":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.title_stored":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.title.en":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.title.alternative":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.title.alternative.en":["Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage"],"dc.type":["Article"],"dc.type.en":["Article"],"publication_grp":["123456789/8819"],"bi_2_dis_filter":["beylerli, ozal\n|||\nBeylerli, Ozal","gareev, ilgiz\n|||\nGareev, Ilgiz","sufianov, albert\n|||\nSufianov, Albert","pavlov, valentin\n|||\nPavlov, Valentin","shi, huaizhang\n|||\nShi, Huaizhang"],"bi_2_dis_partial":["Sufianov, Albert","Gareev, Ilgiz","Pavlov, Valentin","Shi, Huaizhang","Beylerli, Ozal"],"bi_2_dis_value_filter":["Sufianov, Albert","Gareev, Ilgiz","Pavlov, Valentin","Shi, Huaizhang","Beylerli, Ozal"],"bi_4_dis_filter":["intracerebral hemorrhage\n|||\nIntracerebral hemorrhage","stromal vascular fraction\n|||\nStromal vascular fraction","stroke treatment\n|||\nStroke treatment","neuroprotection\n|||\nNeuroprotection","regenerative medicine\n|||\nRegenerative medicine","scopus\n|||\nScopus","mesenchymal stem cells\n|||\nMesenchymal stem cells"],"bi_4_dis_partial":["Neuroprotection","Regenerative medicine","Scopus","Stromal vascular fraction","Stroke treatment","Intracerebral hemorrhage","Mesenchymal stem cells"],"bi_4_dis_value_filter":["Neuroprotection","Regenerative medicine","Scopus","Stromal vascular fraction","Stroke treatment","Intracerebral hemorrhage","Mesenchymal stem cells"],"bi_sort_1_sort":"stromal vascular fraction cell therapy: a promising therapeutic method for intracerebral hemorrhage","bi_sort_2_sort":"2025","bi_sort_3_sort":"2025-05-06T09:27:48Z","read":["g0"],"_version_":1831362905368428544}]},"facet_counts":{"facet_queries":{},"facet_fields":{},"facet_dates":{},"facet_ranges":{},"facet_intervals":{}},"highlighting":{"2-8042":{"bi_4_dis_partial":["interventional surgery"],"dc.subject.en":["interventional surgery"],"dc.citation.en":["Shahid M., Cetera B. Thyroid disease and thyroid surgery. Anaesth Intens Care Med. 2023"],"dc.source":["Creative surgery and oncology"],"dc.subject":["interventional surgery"],"dc.citation.ru":["Shahid M., Cetera B. Thyroid disease and thyroid surgery. Anaesth Intens Care Med. 2023"],"dc.source.en":["Creative surgery and oncology"],"dc.subject_mlt":["interventional surgery"],"dc.abstract.en":[". Conclusion. The study highlights the potential of interventional endocrine surgery as a"],"dc.citation":["Shahid M., Cetera B. Thyroid disease and thyroid surgery. Anaesth Intens Care Med. 2023"],"subject":["interventional surgery"],"dc.abstract":[". Conclusion. The study highlights the potential of interventional endocrine surgery as a"]},"2-8022":{"dc.fullHTML":[" intervention.